Jul 12, 2019
Global Treanda (bendamustine; Teva/Mundipharma/Eisai Drug Overview & Product Profiles 2017-2026
Dec 01, 2018
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Dec 01, 2018
Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
Nov 01, 2018
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Sep 11, 2018
Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
Jun 16, 2018
European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It's as Simple as A-D-C
Jun 15, 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Jun 08, 2018
AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy
Dec 12, 2017
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
Dec 12, 2017
AbbVie Announces Phase 3 Study of VENCLEXTA(TM)/ VENCLYXTO(TM) (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint